Biosynthetic and synthetic strategies for assembling capuramycin-type antituberculosis antibiotics

Ashley L. Biecker; Xiaodong Liu; Jon S. Thorson; Zhaoyong Yang; Steven G. Van Lanen

doi:10.3390/molecules24030433

Biosynthetic and synthetic strategies for assembling capuramycin-type antituberculosis antibiotics

Ashley L. Biecker, Xiaodong Liu, Jon S. Thorson, Zhaoyong Yang, Steven G. Van Lanen

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Mycobacterium tuberculosis (Mtb) has recently surpassed HIV/AIDS as the leading cause of death by a single infectious agent. The standard therapeutic regimen against tuberculosis (TB) remains a long, expensive process involving a multidrug regimen, and the prominence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and totally drug-resistant (TDR) strains continues to impede treatment success. An underexplored class of natural products—the capuramycin-type nucleoside antibiotics—have been shown to have potent anti-TB activity by inhibiting bacterial translocase I, a ubiquitous and essential enzyme that functions in peptidoglycan biosynthesis. The present review discusses current literature concerning the biosynthesis and chemical synthesis of capuramycin and analogs, seeking to highlight the potential of the capuramycin scaffold as a favorable anti-TB therapeutic that warrants further development.

Original language	English
Article number	433
Journal	Molecules
Volume	24
Issue number	3
DOIs	https://doi.org/10.3390/molecules24030433
State	Published - Jan 1 2019

Bibliographical note

Funding Information:
Funding: This research was funded by National Institutes of Health, grant number AI128862 and AI087849 and National Natural Science Foundation of China, grant numbers 81321004 and 81761128016.

Publisher Copyright:
© 2019 by the authors.

Keywords

Antibiotic
Bacterial translocase I
MraY
Mycobacterium tuberculosis
Natural product
Nucleoside

ASJC Scopus subject areas

Analytical Chemistry
Chemistry (miscellaneous)
Molecular Medicine
Pharmaceutical Science
Drug Discovery
Physical and Theoretical Chemistry
Organic Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/molecules24030433

Cite this

@article{ae69fc7a936045269de053f24945d4e0,

title = "Biosynthetic and synthetic strategies for assembling capuramycin-type antituberculosis antibiotics",

abstract = "Mycobacterium tuberculosis (Mtb) has recently surpassed HIV/AIDS as the leading cause of death by a single infectious agent. The standard therapeutic regimen against tuberculosis (TB) remains a long, expensive process involving a multidrug regimen, and the prominence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and totally drug-resistant (TDR) strains continues to impede treatment success. An underexplored class of natural products—the capuramycin-type nucleoside antibiotics—have been shown to have potent anti-TB activity by inhibiting bacterial translocase I, a ubiquitous and essential enzyme that functions in peptidoglycan biosynthesis. The present review discusses current literature concerning the biosynthesis and chemical synthesis of capuramycin and analogs, seeking to highlight the potential of the capuramycin scaffold as a favorable anti-TB therapeutic that warrants further development.",

keywords = "Antibiotic, Bacterial translocase I, MraY, Mycobacterium tuberculosis, Natural product, Nucleoside",

author = "Biecker, {Ashley L.} and Xiaodong Liu and Thorson, {Jon S.} and Zhaoyong Yang and {Van Lanen}, {Steven G.}",

note = "Funding Information: Funding: This research was funded by National Institutes of Health, grant number AI128862 and AI087849 and National Natural Science Foundation of China, grant numbers 81321004 and 81761128016. Publisher Copyright: {\textcopyright} 2019 by the authors.",

year = "2019",

month = jan,

day = "1",

doi = "10.3390/molecules24030433",

language = "English",

volume = "24",

number = "3",

}

TY - JOUR

T1 - Biosynthetic and synthetic strategies for assembling capuramycin-type antituberculosis antibiotics

AU - Biecker, Ashley L.

AU - Liu, Xiaodong

AU - Thorson, Jon S.

AU - Yang, Zhaoyong

AU - Van Lanen, Steven G.

N1 - Funding Information: Funding: This research was funded by National Institutes of Health, grant number AI128862 and AI087849 and National Natural Science Foundation of China, grant numbers 81321004 and 81761128016. Publisher Copyright: © 2019 by the authors.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Mycobacterium tuberculosis (Mtb) has recently surpassed HIV/AIDS as the leading cause of death by a single infectious agent. The standard therapeutic regimen against tuberculosis (TB) remains a long, expensive process involving a multidrug regimen, and the prominence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and totally drug-resistant (TDR) strains continues to impede treatment success. An underexplored class of natural products—the capuramycin-type nucleoside antibiotics—have been shown to have potent anti-TB activity by inhibiting bacterial translocase I, a ubiquitous and essential enzyme that functions in peptidoglycan biosynthesis. The present review discusses current literature concerning the biosynthesis and chemical synthesis of capuramycin and analogs, seeking to highlight the potential of the capuramycin scaffold as a favorable anti-TB therapeutic that warrants further development.

AB - Mycobacterium tuberculosis (Mtb) has recently surpassed HIV/AIDS as the leading cause of death by a single infectious agent. The standard therapeutic regimen against tuberculosis (TB) remains a long, expensive process involving a multidrug regimen, and the prominence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and totally drug-resistant (TDR) strains continues to impede treatment success. An underexplored class of natural products—the capuramycin-type nucleoside antibiotics—have been shown to have potent anti-TB activity by inhibiting bacterial translocase I, a ubiquitous and essential enzyme that functions in peptidoglycan biosynthesis. The present review discusses current literature concerning the biosynthesis and chemical synthesis of capuramycin and analogs, seeking to highlight the potential of the capuramycin scaffold as a favorable anti-TB therapeutic that warrants further development.

KW - Antibiotic

KW - Bacterial translocase I

KW - MraY

KW - Mycobacterium tuberculosis

KW - Natural product

KW - Nucleoside

UR - http://www.scopus.com/inward/record.url?scp=85060549205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060549205&partnerID=8YFLogxK

U2 - 10.3390/molecules24030433

DO - 10.3390/molecules24030433

M3 - Review article

C2 - 30691073

AN - SCOPUS:85060549205

SN - 1420-3049

VL - 24

JO - Molecules

JF - Molecules

IS - 3

M1 - 433

ER -

Biosynthetic and synthetic strategies for assembling capuramycin-type antituberculosis antibiotics

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this